- Home
- IVZ vs HALO Comparison
IVZ vs HALO Comparison
Compare IVZ & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVZ
- HALO
- Stock Information
- Founded
- IVZ 1935
- HALO 1998
- Country
- IVZ United States
- HALO United States
- Employees
- IVZ N/A
- HALO N/A
- Industry
- IVZ Investment Managers
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVZ Finance
- HALO Health Care
- Exchange
- IVZ Nasdaq
- HALO Nasdaq
- Market Cap
- IVZ 6.4B
- HALO 7.4B
- IPO Year
- IVZ 1995
- HALO N/A
- Fundamental
- Price
- IVZ $16.31
- HALO $53.14
- Analyst Decision
- IVZ Hold
- HALO Buy
- Analyst Count
- IVZ 15
- HALO 9
- Target Price
- IVZ $17.42
- HALO $63.56
- AVG Volume (30 Days)
- IVZ 4.9M
- HALO 2.9M
- Earning Date
- IVZ 07-22-2025
- HALO 08-05-2025
- Dividend Yield
- IVZ 5.32%
- HALO N/A
- EPS Growth
- IVZ N/A
- HALO 55.40
- EPS
- IVZ 1.24
- HALO 3.76
- Revenue
- IVZ $6,120,900,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- IVZ N/A
- HALO $25.77
- Revenue Next Year
- IVZ $3.34
- HALO $18.01
- P/E Ratio
- IVZ $12.71
- HALO $13.84
- Revenue Growth
- IVZ 6.02
- HALO 25.64
- 52 Week Low
- IVZ $11.60
- HALO $42.01
- 52 Week High
- IVZ $19.55
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- IVZ 66.06
- HALO 40.94
- Support Level
- IVZ $14.51
- HALO $51.06
- Resistance Level
- IVZ $15.83
- HALO $53.44
- Average True Range (ATR)
- IVZ 0.31
- HALO 1.18
- MACD
- IVZ 0.11
- HALO 0.02
- Stochastic Oscillator
- IVZ 97.83
- HALO 24.89
About IVZ Invesco Ltd
Invesco provides investment-management services to retail (67% of managed assets) and institutional (33%) clients. At the end of April 2025, the firm had $1.840 trillion in assets under management spread among its equity (57% of AUM), balanced (3%), fixed-income (22%), alternative investment (7%), and money market (11%) operations. Passive products account for 43% of Invesco's total AUM, including 65% of the company's equity operations and 15% of its fixed-income platform. Invesco's US retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside of North America, with 30% of its AUM sourced from Europe, Africa, and the Middle East (15%) and Asia (15%).
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.